aponil 100 mg tabletes
medochemie ltd., cyprus - nimesulīds - tablete - 100 mg
dapril 20 mg tabletes
medochemie ltd., cyprus - lizinoprils - tablete - 20 mg
dapril 10 mg tabletes
medochemie ltd., cyprus - lizinoprils - tablete - 10 mg
dapril 5 mg tabletes
medochemie ltd., cyprus - lizinoprils - tablete - 5 mg
sevoflurane piramal 100% inhalācijas tvaiki, šķidrums
piramal critical care b.v., netherlands - sevoflurāns - inhalācijas tvaiki, šķidrums - 100%
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imūnsupresanti - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
ultomiris
alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imūnsupresanti - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
cilvēka albumīns bts 50 g/l šķīdums infūzijām
baltijas terapeitiskais serviss, sia, latvia - albumīns, cilvēka - Šķīdums infūzijām - 50 g/l
avodart 0,5 mg mīkstās kapsulas
glaxosmithkline (ireland) limited, ireland - dutasterīds - kapsula, mīkstā - 0,5 mg